Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Katial

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 5, 2022
Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 StudyYen Chung, Rohit Katial, Fan Mu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 3, 2023
Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe AsthmaEugene R Bleecker, Deborah A Meyers, Dean Billheimer, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 4, 2017
Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthmaBradley E Chipps, Jonathan Corren, Elliot Israel, et al.
Allergy, Asthma & Immunology Research|October 12, 2023
Real-World Investigation of Eosinophilic-Associated Disease Overlap (REVEAL): Analysis of a US Claims DatabaseAnamaria Brailean, Justin Kwiatek, Danuta Kielar, et al.
Advances in Therapy|March 14, 2022
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAndrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Gene Therapy|January 17, 2025
Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trialsMengdie Cao, Rohit Katial, Yanjun Liu, et al.
Advances in Therapy|June 22, 2022
A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"Andrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Clinical Therapeutics|September 3, 2022
Systemic Corticosteroid-related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal PolyposisGreg E Davis, Robert S Zeiger, Benjamin Emmanuel, et al.
Immunotherapy|May 2, 2024
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summaryEmma Guttman-Yassky, Lila Bahadori, Laura Brooks, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 10, 2025
Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group StudyChris Wynne, Ulrike Lorch, Edrich Krantz, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 5, 2022
Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 StudyYen Chung, Rohit Katial, Fan Mu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 3, 2023
Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe AsthmaEugene R Bleecker, Deborah A Meyers, Dean Billheimer, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 4, 2017
Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthmaBradley E Chipps, Jonathan Corren, Elliot Israel, et al.
Allergy, Asthma & Immunology Research|October 12, 2023
Real-World Investigation of Eosinophilic-Associated Disease Overlap (REVEAL): Analysis of a US Claims DatabaseAnamaria Brailean, Justin Kwiatek, Danuta Kielar, et al.
Advances in Therapy|March 14, 2022
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAndrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Gene Therapy|January 17, 2025
Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trialsMengdie Cao, Rohit Katial, Yanjun Liu, et al.
Advances in Therapy|June 22, 2022
A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"Andrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Clinical Therapeutics|September 3, 2022
Systemic Corticosteroid-related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal PolyposisGreg E Davis, Robert S Zeiger, Benjamin Emmanuel, et al.
Immunotherapy|May 2, 2024
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summaryEmma Guttman-Yassky, Lila Bahadori, Laura Brooks, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 10, 2025
Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group StudyChris Wynne, Ulrike Lorch, Edrich Krantz, et al.
Pageof 7